Daiichi Sankyo (OTCMKTS:DSNKY) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Daiichi Sankyo (OTCMKTS:DSNKY) posted its quarterly earnings data on Friday. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.08, Zacks reports. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%.

Daiichi Sankyo Stock Performance

OTCMKTS:DSNKY traded up $0.88 during midday trading on Friday, hitting $17.44. The company’s stock had a trading volume of 96,936 shares, compared to its average volume of 305,904. Daiichi Sankyo has a fifty-two week low of $14.98 and a fifty-two week high of $24.77. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.92 and a quick ratio of 1.96. The firm has a market cap of $32.49 billion, a P/E ratio of 20.28, a P/E/G ratio of 1.73 and a beta of -0.11. The firm’s 50 day moving average is $17.78 and its 200-day moving average is $17.69.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Zacks Research downgraded shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce”.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based global pharmaceutical company that researches, develops, manufactures and markets prescription medicines. The company focuses primarily on oncology, with additional activities in areas such as cardiovascular disease, rare diseases and other specialty therapies. Its products are marketed in Japan and internationally through subsidiaries, partnerships and licensing agreements.

Daiichi Sankyo is particularly known for its antibody-drug conjugate technology, which is designed to deliver cancer-killing agents more selectively to tumor cells.